First Horizon Advisors, Inc. Nuvalent, Inc. Transaction History
First Horizon Advisors, Inc.
- $3.58 Billion
- Q3 2024
A detailed history of First Horizon Advisors, Inc. transactions in Nuvalent, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 12 shares of NUVL stock, worth $1,160. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12
Previous 232
94.83%
Holding current value
$1,160
Previous $17,000
94.12%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding NUVL
# of Institutions
210Shares Held
59.5MCall Options Held
450KPut Options Held
619K-
Deerfield Management Company, L.P. (Series C) New York, NY20MShares$1.93 Billion38.02% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5MShares$483 Million18.43% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.13MShares$400 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$292 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.98MShares$288 Million7.96% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $4.16B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...